France, Nov. 19 -- The French Medicines Agency (ANSM) has taken further action against websites offering products marketed as anti-obesity treatments, following on from an initial swathe of measures taken to stop fraudulent, on-line practices.

In September, the drug regulator announced that it had identified 10 commercial websites illegally advertising and selling products presented as belonging to the "GLP-1 analogues" (aGLP-1) family of drugs used in the treatment of diabetes and/or obesity.

However, the drugs - marketed under the names Ozempic or Wegovy, Saxenda or Victoza, Trulicity or Mounjaro - mimic the action of the GLP-1 hormone that helps regulate blood sugar and appetite, can only be obtained from pharmacies upon the presenta...